Abstract:As an extremely popular natural product, berberine (BER) is mainly used for gastroenteritis and diarrhoea caused by bacteria. Research has also revealed the potent and extensive pharmacological properties of BER including its anti-arrhythmic, anti-tumour, anti-inflammatory and hypoglycemic activities and so on; therefore, BER is a promising drug for further development. However, its commercial form with hydrochloride exhibits poor stability and solubility, which are detrimental to its clinical therapeutic effects. For these purposes, the salt form was regulated via the reactive crystallization of 8-hydroxy-7,8-dihydroberberine (8H-HBER) with five pharmaceutically suitable organic acids including malonic acid (MA), L-tartaric acid (LTA), D-tartaric acid (DTA), DL-tartaric acid (DLTA) and citric acid (CA), resulting in the six novel solid forms 1BER-1LTA-1W, 1BER-1DTA-1W, 1BER-1DLTA and 2BER-2CA as well as two rare multi-stoichiometric solid forms 1BER-1MA and 1BER-2MA-2W. The preparation of the multi-stoichiometric products was greatly influenced by both the crystallization solvent type and the molar ratio of reactants. The structures of these multi-component solid forms were determined using single-crystal X-ray diffraction and further characterized by powder X-ray diffraction, thermal analysis and Fourier transform infrared spectroscopy. Stability experiments showed that all samples prepared had superior physical stability under high temperature and high humidity. Furthermore, dissolution experiments demonstrated that the maximum apparent solubilities (MAS) of all the products were significantly improved compared with the commercial form of BER in dilute hydrochloric solution (pH = 1.2). In particular, the MAS of 1BER-1MA in dilute hydrochloric solution is as high as 34 times that of the commercial form. In addition, it is preliminarily confirmed that the MAS of the samples prepared in pure water and dilute hydrochloric solution is primarily influenced by a combination of factors including the packing index, intermolecular interactions, affinity of the counter-ion to the solvent, the molar ratio of the drug to counter-ion in the product and the common ion effect. These novel solids are potential candidates for BER solid forms with improved oral dosage design and may prompt further development.

Preparation, characterization, and stability enhancement of metoprolol pharmaceutical multicomponent crystals

Novel multi-component crystals of berberine with improved pharmaceutical properties

Sustainable preparation of spherical particles of novel carbamazepine-hesperetin cocrystal via different crystallization strategies: From mechanism to application

Preparation, Characterization and in Vivo Evaluation of Pharmacological Activity of Different Crystal Forms of Ibuprofen

Enhancing Stability and Formulation Capability of Fungicides by Cocrystallization Through a Novel Multistep Slurry Conversion Process

Preparation, characterization, and crystal structures of novel sophocarpine salts with improvements on stability and solubility

Novel Drug–Drug Multicomponent Crystals of Epalrestat–Metformin: Improved Solubility and Photostability of Epalrestat and Reduced Hygroscopicity of Metformin

Chemical stabilization strategy for cymoxanil: synthesis and characterization of cocrystals with small organic acids

Pharmaceutical Multicomponent Crystals: Structure, Design, and Properties

Solution Stability of Pharmaceutical Cocrystals

Pharmaceutical cocrystals, salts and polymorphs: Advanced characterization techniques

Melt Crystallization of Celecoxib-Carbamazepine Cocrystals with the Synchronized Release of Drugs

Dissolution Performance Enhancement of Poorly Water-Soluble API by Crystallization from Phase-Separated Melt

Amorphous Solid Dispersions: Implication of Method of Preparation and Physicochemical Properties of API and Excipients

Fabrication of Micro Spherulitic Particles of Carbamazepine-Hesperetin Cocrystal Via QESD with Enhanced Manufacturability and Dissolution

Particle design of the metastable form of clopidogrel hydrogen sulfate by building spherulitic growth operating spaces in binary solvent systems

Advanced Chemical And Imaging Methods For Studying Structure Morphology And Excipients Solid State Transformations In Pharmaceutical Multiparticulate Formulations

In-situ sequential crystallization of fenofibrate and tristearin - Understanding the distribution of API in particles and stability of solid lipid microparticles from the perspective of crystallization

Improving the Physicochemical and Biopharmaceutical Properties of Active Pharmaceutical Ingredients Derived from Traditional Chinese Medicine through Cocrystal Engineering

A Drug–Drug Cocrystal Strategy to Regulate Stability and Solubility: A Case Study of Temozolomide/Caffeic Acid

Investigation into the structures and physicochemical properties of multi-component crystals of voriconazole